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The role of JNK in the development
of hepatocellular carcinoma
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The cJun NH2-terminal kinase (JNK) signal transduction pathway has been implicated in the growth of
carcinogen-induced hepatocellular carcinoma. However, the mechanism that accounts for JNK-regulated tumor
growth is unclear. Here we demonstrate that compound deficiency of the two ubiquitously expressed JNK
isoforms (JNK1 and JNK2) in hepatocytes does not prevent hepatocellular carcinoma development. Indeed, JNK
deficiency in hepatocytes increased the tumor burden. In contrast, compound JNK deficiency in hepatocytes and
nonparenchymal cells reduced both hepatic inflammation and tumorigenesis. These data indicate that JNK plays
a dual role in the development of hepatocellular carcinoma. JNK promotes an inflammatory hepatic environment
that supports tumor development, but also functions in hepatocytes to reduce tumor development.
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The cJun NH2-terminal kinase (JNK) pathway is impli-
cated in tumor development (Davis 2000). Targets of
JNK signaling include members of the activating protein
1 (AP1) transcription factor group (e.g., cJun, JunB, JunD,
and related proteins). These transcription factors function
within a regulatory network that controls multiple as-
pects of cellular physiology, including proliferation (Eferl
and Wagner 2003). Studies of murine embryo fibroblasts
(MEFs) demonstrate that loss of JNK causes major defects
in cellular proliferation (Tournier et al. 2000) and AP1-
dependent gene expression (Ventura et al. 2003). These
effects of JNK are mediated, in part, by the AP1 tran-
scription factor. Indeed, cJun phosphorylation is required
for normal serum-stimulated cell growth (Behrens et al.
1999). The JNK signaling pathway therefore represents
an important regulatory mechanism that can control
growth. Moreover, dysregulated JNK may contribute to
tumor development (Davis 2000).
Studies of the role of the JNK and cJun in the liver have
confirmed the importance of this signaling pathway in
growth regulation. Thus, cJun-deficient mice (Behrens
et al. 2002; Stepniak et al. 2006), JNK1-deficient mice
(Hui et al. 2008), and mice treated with a JNK inhibitor
(Schwabe et al. 2003) exhibit major defects in liver re-
generation following partial hepatectomy (PHx). Further-
more, both cJun-deficient mice (Eferl et al. 2003) and
JNK1-deficient mice (Sakurai et al. 2006; Hui et al. 2008)
are protected against the development of hepatocellular
carcinoma (HCC) following exposure to the carcinogen
diethylnitrosamine (DEN). The critical role of JNK in
HCC has been confirmed by pharmacological inhibition
of JNK and studies of human HCC cells (Hui et al. 2008).
The mechanism of JNK and cJun signaling in the liver
that contributes to regeneration and HCC is unclear, but
down-regulation of the proliferation inhibitor p21CIP1 and
up-regulation of the growth promoter cMyc appear to be
critical factors (Stepniak et al. 2006; Hui et al. 2008). An
alternative mechanism for the contribution of JNK to
HCC is represented by the role of compensatory pro-
liferation in hepatic tumor development (Fausto 1999). It
has been reported that JNK1 is required for hepatocyte
death in the DEN model of HCC (Sakurai et al. 2006).
Reduced hepatocyte death in JNK1-deficient mice results
in reduced compensatory proliferation and suppression
of HCC (Sakurai et al. 2006). These mechanisms are not
mutually exclusive, and it is possible that JNK plays
multiple roles in HCC, including regulation of cell death
and gene expression. Nevertheless, a common theme
among these mechanisms is that JNK plays a critical role
in hepatocytes that is required for HCC development.
The purpose of this study was to examine the role of
JNK in the development of HCC. Specifically, we tested
whether JNK in hepatocytes contributes to tumor forma-
tion. Previous studies have focused on an analysis of
Jnk1/ mice (Sakurai et al. 2006; Hui et al. 2008). Here
we report the analysis of mice with tissue-specific de-
ficiency of JNK and mice with compound deficiency of
both JNK1 and JNK2. Our analysis demonstrates that
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compound JNK deficiency in hepatocytes increases the
development of HCC. JNK therefore functions in liver
parenchymal cells to reduce tumor development. We
show that the protumorigenic effects of JNK on HCC
are associated with inflammation and require JNK func-
tion in nonparenchymal cells.
Results
Compound JNK deficiency in hepatocytes
does not prevent liver regeneration following PHx
PHx causes JNK activation and a robust regeneration
response that results in rapid restoration of liver mass
(Westwick et al. 1995). It has been reported that Jnk1/
mice exhibit a defect in the regeneration response to PHx
(Hui et al. 2008). In initial studies, we compared hepatic
regeneration in control mice, Jnk1/ mice, and Jnk2/
mice following PHx. This analysis demonstrated similar
hepatic regeneration in control and Jnk2/ mice, but
hepatic regeneration was suppressed in Jnk1/ mice
(Supplemental Fig. S1). These data indicate that JNK1
may play an important role in hepatocyte proliferation
(Hui et al. 2008).
The Jnk1 and Jnk2 genes are both expressed in hepato-
cytes (Davis 2000). Consequently, the reduced hepatic
regeneration detected in Jnk1/mice (Supplemental Fig.
S1) is not caused by loss of total JNK in hepatocytes.
These considerations indicated that studies of hepatic
regeneration in mice with compound ablation of Jnk1
plus Jnk2 are required. We employed a conditional gene
ablation strategy using Alb-Cre transgenic mice to create
animals with compound deficiency of JNK1 plus JNK2 in
hepatocytes (Das et al. 2009). Control HWT mice (Alb-
Cre+/) and JNK-deficient HDJNK mice (Alb-Cre+/
Jnk1LoxP/LoxP Jnk2/) were examined following PHx or
a sham surgical procedure (Fig. 1A).
Biochemical analysis of the liver of HWT and HDJNK
mice at 48 h post-PHx demonstrated that JNK deficiency
did not significantly change the expression of cJun, JunB,
or Cyclin D1 mRNA, but a modest reduction in JunD
Figure 1. JNK deficiency in hepatocytes does not prevent liver regeneration after PHx. (A) Control mice (HWT mice: Alb-Cre-/+) and
JNK-deficient mice (HDJNK mice: Alb-Cre-/+ Jnk1LoxP/LoxP Jnk2/) were subjected to two-thirds PHx or a sham procedure. The mice
were injected (i.p.) with 100 mg/g BrdU (dissolved in saline) at 2 h prior to euthanasia. Representative sections of liver from mice at 48 h
post-surgery were stained with H&E (top panels) and an antibody to BrdU (bottom panels). (B) The liver/body weight ratio was
calculated and expressed as the mean percentage 6 SD (n = 6 mice) in HWT and HDJNK mice. No statistically significant differences
between HWT and HDJNK mice were detected. (C) The percentage of BrdU-positive hepatocytes in HWT and HDJNK mice (mean 6 SD; n =
8 mice) is presented. Statistically significant differences between HWT and HDJNK mice are indicated. (*) P < 0.05; (**) P < 0.001. (D) The
percentage of hepatocyte mitotic figures detected in H&E-stained sections of liver from HWT and HDJNK mice (mean6 SD; n = 8 mice) is
presented. Statistically significant differences between HWT and HDJNK mice are indicated. (*) P < 0.05.
JNK and hepatocellular carcinoma
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mRNA expressionwas detected in the liver of HDJNKmice
compared with HWTmice (Supplemental Fig. S2A). These
changes were associated with reduced activation of JNK
and reduced phosphorylation of cJun in the liver of HDJNK
mice compared with HWT mice (Supplemental Fig. S2B).
These observations are consistent with ablation of the
JNK signaling pathway in the hepatocytes of HDJNK mice.
We detected no statistically significant changes in acti-
vation of AKT or the ERK and p38 MAPKs in the JNK-
deficient liver compared with control liver (Supplemental
Fig. S2B).
Measurement of hepatic mass demonstrated that com-
pound deficiency of JNK1 plus JNK2 in hepatocytes
caused no significant change in regeneration (Fig. 1B).
To confirm this conclusion, we examined hepatocyte
proliferation by measuring the incorporation of bromo-
deoxyuridine (BrdU) (Fig. 1A). This analysis demonstrated
increased BrdU incorporation at 48 h post-PHx in both
HWT and HDJNK mice, but the amount of BrdU incorpora-
tion was reduced inHDJNKmice compared with HWTmice
(Fig. 1C). This reduction in BrdU incorporation is consis-
tent with the reduced number of mitotic figures detected
in hepatocytes of HDJNK mice compared with HWT mice
at 48 h post-PHx (Fig. 1D). However, a time-course analy-
sis demonstrated that the overall hepatic proliferation in
HWT and HDJNK mice following PHx was similar (Fig.
1C,D). These data demonstrate that compound JNK de-
ficiency does not prevent hepatic regeneration following
PHx.
The discovery that mice with compound JNK defi-
ciency in hepatocytes were capable of hepatic regenera-
tion following PHxwas unexpected for two reasons. First,
hepatic regeneration is strongly reduced in Jnk1/ mice
(Supplemental Fig. S1; Hui et al. 2008). Second, studies of
Jnk1/ Jnk2/ primary MEFs demonstrate that these
JNK-deficient cells exhibit severe defects in proliferation,
including early senescence (Tournier et al. 2000; Das et al.
2007). Compound JNK deficiency was therefore antici-
pated to similarly cause growth retardation in other cell
types, including hepatocytes. We therefore sought to con-
firm that liver regeneration following PHx is JNK-in-
dependent using a different mouse model with compound
hepatic JNK deficiency (Supplemental Fig. S3). Together,
these data confirm the conclusion that hepatic regenera-
tion following PHx occurs in mice with deficiency of both
JNK1 and JNK2 in the liver (Fig. 1; Supplemental Fig. S3).
JNK is therefore not essential for hepatic regeneration.
JNK deficiency in hepatocytes promotes HCC
The conclusion that JNK is not essential for hepatic
regeneration led us to question whether JNK is required
for hepatocyte proliferation in the context of HCC. We
therefore tested whether JNK in hepatocytes is required
for HCC development by treating HWT and HDJNK mice
with the carcinogen DEN. Previous reports indicate that
DEN-induced HCC is markedly reduced in Jnk1/mice
(Sakurai et al. 2006; Hui et al. 2008). In contrast, we found
that HDJNK mice developed HCC following exposure to
DEN (Fig. 2A; Supplemental Fig. S4). Indeed, the tumor
size in HDJNK mice was significantly greater than in
HWT mice (Fig. 2B). However, no significant difference in
tumor incidence or the number of tumor nodules be-
tween HWT and HDJNK mice was detected (Fig. 2C). This
effect of JNK deficiency to increase HCC was associated
with increased hepatic expression of cJun (Supplemental
Figure 2. Effect of hepatocyte-specific JNK
deficiency on HCC. (A) DEN-induced HCC
in control mice (HWT mice: Alb-Cre+/) and
JNK-deficient mice (HDJNK mice: Alb-Cre+/
Jnk1LoxP/LoxP Jnk2/) at 38 wk of age. (B)
The maximum diameter of individual tu-
mor nodules (right panel) and the mean 6
SD (n = 13) width of the tumor nodules (left
panel) are presented. Statistically signifi-
cant differences between HWT and HDJNK
mice are indicated. (*) P < 0.05. (C) The
tumor incidence (left panel) and the number
of tumors per mouse (right panel) were
examined (n = 14). No statistically signifi-
cant differences between HWT and HDJNK
mice were detected. (D) Representative sec-
tions of liver from mice treated without
DEN (control) and with DEN (tumor)
stained with H&E are presented. (E) Immu-
noblot analysis of tumors isolated from
HWT mice and HDJNK mice was performed
by probing with antibodies to JNK and a-Tu-
bulin (Tub.). (F) Kaplan-Meier analysis of the
survival of HWT mice and HDJNK mice (n =
10) treated with DEN is presented. No sta-
tistically significant difference between the
survival or mortality of HWT mice and HDJNK
mice was detected (log-rank test; P = 0.055).
Das et al.
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Fig. S5A). Histological analysis of hepatic sections dem-
onstrated the presence of lesions ranging from adenoma
to carcinoma in HWT mice, but primarily carcinoma in
HDJNK mice (Fig. 2D; Supplemental Figs. S6, S7). Immu-
noblot analysis demonstrated that HDJNK tumors were
JNK deficient (Fig. 2E). Together, these data indicate that
JNK in hepatocytes acts as to reduce tumor development
in this model of HCC. However, Kaplan-Meier analysis
demonstrated that the increased tumor burden in theHDJNK
mice did not cause a statistically significant (P = 0.055)
change in survival compared with HWT mice (Fig. 2F).
JNK deficiency can prevent HCC development
The finding that JNK in hepatocytes acts to reduce HCC
(Fig. 2) was not anticipated because studies of Jnk1/
mice (but not Jnk2/ mice) have indicated that JNK
plays a critical role in HCC development (Sakurai et al.
2006; Hui et al. 2008). Together, these findings suggest
that JNK may both inhibit and promote tumor formation
during DEN-induced HCC development. The protumori-
genic role of JNK does not require the function of JNK in
hepatocytes (Fig. 2), but may involve functions of JNK
in nonparenchymal cells. To test this hypothesis, we ex-
amined DEN-induced HCC development in mice with
compound JNK deficiency using Mx-1-Cre mice and
conditional gene ablation in hepatocytes and nonparen-
chymal cells (Das et al. 2009).
Control MxWT mice (Mx-1-Cre+/) and JNK-deficient
MxDJNK mice (Mx-1-Cre+/ Jnk1LoxP/LoxP Jnk2/) were
tested for HCC development. We found that HCC was
strongly suppressed inMxDJNK mice compared withMxWT
mice (Fig. 3A; Supplemental Fig. S4). The tumor size in
MxDJNKmicewas significantly smaller than inMxWTmice
(Fig. 3B). Moreover, both the tumor incidence and the
number of tumor nodules were reduced in MxDJNK mice
compared with MxWT mice (Fig. 3C). This effect of JNK
deficiency to suppress HCCwas associated withmarkedly
reduced hepatic expression of cJun (Supplemental Fig.
S5B). Histological analysis of hepatic tissue sections dem-
onstrated lesions ranging from adenoma to carcinoma in
MxWT mice, but primarily only localized adenoma were
detected in MxDJNK mice (Fig. 3D; Supplemental Figs. S7,
S8). Immunoblot analysis demonstrated that MxDJNK tu-
mors were JNK-deficient (Fig. 3E). Kaplan-Meier analysis
demonstrated that the reduced tumor burden in MxDJNK
mice caused significantly increased survival (P = 0.017)
compared with MxWT mice (Fig. 3F). Together, these data
demonstrate that JNK can play a protumorigenic role in
HCC development. This protumorigenic role does not
require JNK in hepatocytes (Fig. 2), but does require JNK
in nonparenchymal cells (Fig. 3).
JNK regulation of HCC proliferation mediated
by p21CIP1 and cMyc
JNK-mediated transcriptional down-regulation of the
growth inhibitor p21CIP1 and up-regulation of the growth
promoter cMyc have been implicated as critical steps
during HCC development (Hui et al. 2008). We therefore
examined p21CIP1 and cMyc expression in the liver of
mice with compound deficiency of JNK1 plus JNK2 (Fig.
4). We found that p21CIP1 expression was significantly
increased in DEN-treated JNK-deficient mice (HDJNK and
Figure 3. Effect of hepatic JNK deficiency
on HCC. (A) DEN-induced HCC in control
mice (MxWT mice: Mx1-Cre+/) and JNK-
deficient mice (MxDJNK mice: Mx1-Cre+/
Jnk1LoxP/LoxP Jnk2/) at 38 wk of age. The
JNK-deficient mice lack expression of
JNK1 plus JNK2 in both hepatocytes and
nonparenchemyal hepatic cells. (B) The
maximum diameter of individual tumor
nodules (right panel) and the mean 6 SD
(n = 13) width of the tumor nodules (left
panel) are presented. Statistically signif-
icant differences between MxWT and
MxDJNK mice are indicated. (*) P < 0.05;
(**) P < 0.01. (C) The tumor incidence (left
panel) and the number of tumors per
mouse (right panel) were examined (n =
16). Statistically significant differences
between MxWT and MxDJNK mice are in-
dicated. (*) P < 0.05. (D) Representative
sections of liver from mice treated without
DEN (control) and with DEN (tumor)
stained with H&E are presented. (E) Immu-
noblot analysis of tumors isolated from
MxWT mice and MxDJNK mice was per-
formed by probing with antibodies to JNK
and a-Tubulin (Tub.). (F) Kaplan-Meier anal-
ysis of the survival of MxWT mice and MxDJNK mice (n = 11) treated with DEN is presented. The survival of MxWT mice was
significantly shorter than MxDJNK mice (log-rank test; P = 0.017).
JNK and hepatocellular carcinoma
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MxDJNK) compared with DEN-treated control mice (HWT
andMxWT) (Fig. 4). Since HCC is increased in HDJNK mice
(Fig. 2) and decreased in MxDJNK mice (Fig. 3), these data
demonstrate no correlation between p21CIP1 expression
and HCC development in compound JNK-deficient mice.
In contrast, an association between JNK, expression of
cMyc, and HCC development was detected. No signifi-
cant difference between cMyc expression between tu-
mors in mice with (HDJNK) and without (HWT) compound
JNK deficiency in hepatocytes was observed (Fig. 4A).
However, cMyc expression in tumors of mice with
compound JNK deficiency in hepatocytes plus nonpar-
enchymal cells (MxDJNK) was strongly reduced compared
with tumors of control (MxWT) mice (Fig. 4B). This down-
regulation of cMyc expression (Fig. 4B) correlates with
markedly decreased expression of Cyclin D1 (Fig. 4B) and
decreased tumor formation (Fig. 3). Together, these data
support a potential role for JNK-regulated expression of
cMyc, but not p21CIP1, during HCC development.
JNK regulates compensatory proliferation during
HCC development
It is established that compensatory hepatocyte prolifer-
ation plays a major role in the development of HCC
(Fausto 1999). This form of hepatocyte proliferation rep-
resents a regenerative response to hepatocyte death that
is associated with inflammation (Grivennikov et al. 2010).
We therefore examined hepatocyte proliferation and death
in control mice (HWTandMxWT) andmicewith compound
deficiency of JNK1 plus JNK2 (HDJNK and MxDJNK) follow-
ing treatment with DEN. Sections of liver tumors were
stained for the proliferation marker PCNA (Fig. 5A,B) and
for cell death using the TUNEL assay (Fig. 5C,D). We also
examined caspase activation by immunoblot analysis of
Caspase 3 processing to the activated form (Supplemental
Fig. S9). Studies of mice with hepatocyte-specific com-
pound JNK deficiency (HDJNK mice) demonstrated in-
creased cell death and increased proliferation compared
with control HWT mice (Fig. 5A,C; Supplemental Fig. S9).
In contrast, compound deficiency of JNK in hepatocytes
plus nonparenchymal cells (MxDJNK mice) caused both
reduced cell death and reduced proliferation compared
with control MxWT mice (Fig. 5B,D; Supplemental Fig.
S9). These data suggest that decreased compensatory pro-
liferation may account for the reduction in tumor growth
caused by JNK in hepatocytes, and that increased com-
pensatory proliferation may account for the protumor-
genic activity of JNK in nonparenchymal cells.
JNK regulates the expression of hepatic cytokines
The compensatory proliferation caused by hepatocyte
death (Fausto 1999) may be mediated by the release of
IL1a by necrotic cells (Chen et al. 2007; Sakurai et al.
2008) and the subsequent expression of protumorigenic
IL6 (and also TNFa in obese mice) by hepatic innate
immune cells (Naugler et al. 2007; Park et al. 2010).
Indeed, HCC development in mice can be suppressed by
ablation of the Il6 and Tnfa genes (Naugler et al. 2007;
Park et al. 2010). We therefore examined the expression
of inflammatory cytokines in control and JNK-deficient
mice (Fig. 6). Studies of mice with compound deficiency
of JNK1 plus JNK2 in hepatocytes (HDJNK mice) demon-
strated that JNK deficiency caused increased hepatic
expression of Il1a, Il1b, Il6, and Tgfb1 mRNA (Fig. 6A;
Supplemental Fig. S10). In contrast, studies of mice with
compound deficiency of JNK1 and JNK2 in hepatocytes
plus nonparenchymal cells (MxDJNK mice) demonstrated
that JNK deficiency caused decreased expression of Il1a,
Il1b, Il6, Tgfb1, and Tnfa mRNA (Fig. 6B; Supplemental
Fig. S10).
Together, these data indicate that JNK deficiency in
hepatocytes (HDJNK mice) causes increased cell death (Fig.
5C; Supplemental Fig. S9), increased expression of in-
flammatory cytokines (Figs. 6A; Supplemental Fig. S10),
and increased compensatory hepatocyte proliferation
(Fig. 5A). However, JNK deficiency in hepatocytes plus
nonparenchymal cells (MxDJNK mice) causes decreased
cell death (Fig. 5D; Supplemental Fig. S9), decreased
expression of inflammatory cytokines (Figs. 6B; Supple-
mental Fig. S10), and decreased compensatory hepatocyte
proliferation (Fig. 5B). The primary actions of JNK dis-
rupted in HDJNK mice may reflect a role for JNK in cell
survival (Lamb et al. 2003) and thus decreased compensa-
tory proliferation. The primary actions of JNK disrupted in
Figure 4. Effect of JNK deficiency on p21CIP1 and cMyc
expression in HCC. Mice were treated without (Con) or with
DEN and euthanized at 38 wk of age. The expression of p21CIP1,
cMyc, and Cyclin D1 mRNA was examined by RT–PCR using
TaqMan assays. The data presented are normalized for the amount
of Gapdh mRNA in each sample and represent the mean 6 SD
(n = 5). Statistically significant differences are indicated. (*) P <
0.05. (A) Control mice (HWT) and mice with JNK deficiency in
hepatocytes (HDJNK). (B) Control mice (MxWT) and mice with JNK
deficiency in hepatocytes and nonparenchymal cells (MxDJNK).
Das et al.
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MxDJNK mice may be expression of the protumorigenic
cytokines IL6 and TNFa (Sabio et al. 2008; Das et al. 2009).
The role of IL6 in JNK-regulated development of HCC
It is established that IL6 plays a key role in hepatocyte
proliferation (Cressman et al. 1996), and that IL6 is
critically required for DEN-induced HCC (Naugler et al.
2007). We therefore examined the hepatic IL6 signaling
pathway in mice with compound JNK deficiency. Treat-
ment of control mice with DEN caused an increase in
hepatic Il6 mRNA and IL6 protein in the blood (Fig. 6).
The Socs3 gene is a target of IL6-stimulated STAT3
signaling in the liver. Treatment of mice with DEN
caused increased Socs3 mRNA expression (Fig. 6). This
DEN-induced increase in Socs3 gene expression was
suppressed in MxDJNK mice (Fig. 6B) and potentiated in
HDJNK mice (Fig. 6A). These data are consistent with the
increased HCC and hepatic IL6 expression in HDJNK mice
(Figs. 2, 6A) and reduced HCC and hepatic IL6 expression
in MxDJNK mice (Figs. 3, 6B).
The miR-21 gene has been identified as a target of in-
flammatory signaling pathways, including IL6 (Jazbutyte
and Thum 2010). Indeed, treatment of mice with IL6
caused increased hepatic expression of miR-21 (Supple-
mental Fig. S11), and it is established that IL6-induced
miR-21 expression is mediated by two conserved STAT3-
binding sites in themiR-21 promoter (Loffler et al. 2007).
The expression of miR-21 in the liver is increased during
HCC development (Kutay et al. 2006; Meng et al. 2007;
Connolly et al. 2008; Jiang et al. 2008), and studies using a
knockdown approach demonstrate that miR-21 contrib-
utes to HCC proliferation (Connolly et al. 2008). These
data establish that miR-21 plays an important role in
HCC development.
We examined the effect of JNK deficiency on hepatic
expression ofmiR-21. Control studies demonstrated that
DEN caused increased expression ofmiR-21 (Supplemen-
tal Fig. S12). Hepatocyte-specific JNK deficiency (HDJNK
mice) caused increasedmiR-21 expression comparedwith
control (HWT) mice following treatment with DEN (Sup-
plemental Fig. S13A). In contrast, DEN-treated mice with
JNK deficiency in hepatocytes and nonparenchymal cells
(MxDJNK) expressed reduced miR-21 compared with con-
trol (MxWT) DEN-treated mice (Supplemental Fig. S13A).
These effects of JNK deficiency onmiR-21 expression are
consistent with the observed increase (HDJNK) and de-
crease (MxDJNK) in the expression of hepatic IL6 (and other
inflammatory cytokines) following DEN treatment (Fig.
6; Supplemental Fig. S10).
Targets ofmiR-21 include repressors of the AKT (Pten)
and receptor tyrosine kinase (Sprouty) signaling pathways
(Cabrita and Christofori 2008). We therefore examined
Pten and Sprouty expression in DEN-treated control
(MxWT) mice and JNK-deficient (MxDJNK) mice. JNK de-
ficiency did not change the expression of Pten or Sprouty
mRNA (Supplemental Fig. S13C,D). Similarly, JNK de-
ficiency did not cause altered expression of PTEN protein
(Supplemental Fig. S13D). In contrast, JNK deficiency
caused increased expression of Sprouty protein (Supple-
mental Fig. S13C). To test whether this increased expres-
sion of Sprouty is functionally relevant, we examined
signaling pathways downstream from activated receptor
tyrosine kinases, including AKT and ERK. We found that
increased expression of the negative regulator Sprouty in
JNK-deficient (MxDJNK) mice was associated with reduced
AKT and ERK activity (Supplemental Fig. S13B). These
data suggest that Sprouty (Supplemental Fig. S13C) may
be a relevant target of the miR-21 pathway that is
required for HCC development (Connolly et al. 2008).
Figure 5. Effect of JNK deficiency on he-
patocyte death and compensatory prolifera-
tion. (A–D) Control mice (HWT and MxWT)
and JNK-deficient (DJNK) mice (HDJNK and
MxDJNK) were treated with DEN. Hepatic
tissue sections of mice (age 38 wk) were
examined by staining with an antibody to
the proliferation marker PCNA (A,B) or by
TUNEL assay (C,D). DNAwas stained with
DAPI. Quantitation of triplicate indepen-
dent samples demonstrated that 29.0% 6
1.1% of HWT and 49.9% 6 7.2% of HDJNK
nuclei were positive for PCNA (P < 0.05),
61.1% 6 12.5% of MxWT and 17.4% 6
1.4% of MxDJNK nuclei were positive for
PCNA (P < 0.05), 2.5% 6 1.2% of HWT and
32.4% 6 6.1% of HDJNK nuclei were TUNEL-
positive (P < 0.01), and 44.2% 6 6.6% of
MxWT and 10.7% 6 2.3% of MxDJNK nuclei
were TUNEL-positive (P < 0.01).
JNK and hepatocellular carcinoma
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Discussion
The role of JNK in proliferation is cell type-dependent
It is established that JNK is critically required for the
proliferation of primary MEFs (Davis 2000). Compound
mutant Jnk1/ Jnk2/ MEFs exhibit a severe growth
retardation phenotype (Tournier et al. 2000) and prema-
ture senescence (Das et al. 2007). The rapid senescence of
primary Jnk1/ Jnk2/ MEFs is mediated by increased
expression of the Trp53 tumor suppressor (Das et al.
2007). This engagement of p53-dependent senescence in
primary Jnk1/ Jnk2/MEFs (Das et al. 2007) is similar
to cJun/ MEFs (Schreiber et al. 1999). Indeed, reduced
expression of cJun by Jnk1/ Jnk2/ MEFs may con-
tribute to the early senescence phenotype (Ventura et al.
2003). These observations indicate that JNK may have
a general role in the proliferation of many cell types.
Reports that JNK1 plays an essential role in both hepatic
regeneration following PHx (Hui et al. 2008) and
DEN-induced HCC (Sakurai et al. 2006; Hui et al. 2008)
are consistent with this conclusion.
The finding that compound JNK deficiency does not
prevent hepatocyte proliferation was unexpected (Figs. 1,
2; Supplemental Fig. S3). The simplest explanation for
these data is that JNK is not required for proliferation
of hepatocytes (Fig. 1; Supplemental Fig. S3), but JNK is
Figure 6. Effect of JNK deficiency on the expression of
hepatic cytokines. (A,B) HWT and HDJNK mice (A) or
MxWT and MxDJNK mice (B) were treated without (Con)
or with DEN and euthanized at 38 wk of age. The blood
concentration of IL6 was measured by ELISA and is
presented as the mean 6 SD (n = 7). Total RNA was
isolated from the liver, and the expression of Il1a, Il1b,
Il6, Socs3, and Tnfa mRNA was examined by RT–PCR
using TaqMan assays. The data presented are normal-
ized for the amount of Gapdh mRNA in each sample
and represent the mean 6 SD (n = 5). Statistically
significant differences between the control and JNK-
deficient mice are indicated (P < 0.05).
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selectively required to prevent Trp53-dependent senes-
cence of MEFs (Das et al. 2007). Cell type-specific re-
sponses to JNK deficiency may reflect differences in the
requirement of JNK for the expression of cJun, a repressor
of the Trp53 promoter (Schreiber et al. 1999). Compound
JNK deficiency in MEFs causes down-regulation of cJun
expression (Ventura et al. 2003). In contrast, compound
JNK deficiency in hepatocytes did not cause significantly
decreased cJun expression (Supplemental Fig. S2A). The
failure of JNK deficiency to down-regulate cJun expres-
sion in hepatocytes may reflect signaling pathway re-
dundancy, including roles of JNK in AP1-dependent
cJun expression (Ventura et al. 2003) and p38 MAPK in
MEF2-dependent cJun expression (Han et al. 1997).
Indeed, it is intriguing that the p38 MAPK pathway in
hepatocytes is constitutively activated and subject to
metabolic regulation (Mendelson et al. 1996), but p38
MAPK is stress-inducible from a low basal activity in
MEFs (Raingeaud et al. 1995). The p38 MAPK pathway
may therefore act redundantly with JNK to regulate
cJun expression in hepatocytes, but the p38 MAPK
pathway may not compensate for JNK deficiency in
MEFs. Cross-talk, partially redundant signaling, and
partially antagonistic signaling by the JNK and p38
MAPK pathways may therefore contribute to the tis-
sue-specific effects of JNK on proliferation (Wagner and
Nebreda 2009).
The role of JNK in liver regeneration
The function of JNK in hepatocytes and nonparenchymal
cells of the liver is not required for hepatic regeneration
following PHx (Fig. 1; Supplemental Fig. S3). Neverthe-
less, liver regeneration is reduced in Jnk1/ mice (Sup-
plemental Fig. S1; Hui et al. 2008). The mechanism that
accounts for this phenotype of Jnk1/ mice is unclear.
The simplest hypothesis is that JNK1 plays a critical role
in a nonhepatic tissue, and that this JNK1-dependent
function is disrupted in Jnk1/mice. The identity of the
relevant tissue that mediates JNK1-dependent hepatic
regeneration has not been established. One possibility is
represented by the hypothalamus, a region of the brain
that strongly influences liver regeneration (Kiba 2002).
This possibility is consistent with the discovery that the
major metabolic phenotypes of Jnk1/ mice are largely
accounted for by the effects of JNK1 deficiency in the
hypothalamus, rather than in peripheral tissues (Belgardt
et al. 2010; Sabio et al. 2010). A goal for further studies
will be to identify the specific tissue that accounts for the
required role of JNK1 for hepatic regeneration. This role
of JNK1 contrasts with the absence of a requirement for
hepatic JNK during liver regeneration following PHx (Fig.
1; Supplemental Fig. S3).
The role of JNK in the promotion of HCC
It is established that JNK plays a key role in the de-
velopment of DEN-induced HCC (Sakurai et al. 2006; Hui
et al. 2008). Two mechanisms have been reported to
account for JNK-mediated protumorigenic activity. First,
JNK1 may be required for down-regulation of p21CIP1
expression and up-regulation of cMyc expression (Hui
et al. 2008). Our analysis demonstrates that p21CIP1 ex-
pression does not correlate with tumorigenic potential in
studies of HCC development in compound JNK-deficient
mice (HDJNK and MxDJNK) (Fig. 4). In contrast, expression
of cMyc (Fig. 4) correlates with the tumor burden in
HDJNK and MxDJNK mice (Figs. 2, 3). These data are con-
sistent with a role for cMyc in JNK-dependent formation
of HCC (Hui et al. 2008).
A second proposed mechanism is that JNK1 causes
hepatocyte death (Sakurai et al. 2006), resulting in com-
pensatory proliferation that contributes to the development
of HCC (Fausto 1999). However, compound deficiency of
JNK1 and JNK2 in hepatocytes (HDJNK mice) does not
inhibit hepatocyte death following treatment with DEN
(Fig. 5C; Supplemental Fig. S9). These data demonstrate
that JNK-mediated hepatocyte death does not contribute to
compensatory proliferation and HCC. This analysis in-
dicates that another mechanism must account for the
protumorigenic effects of JNK on HCC development.
The observation that compound JNK deficiency in
hepatocytes (HDJNK mice) does not reduce DEN-induced
HCC (Fig. 2), but compound JNK deficiency in hepato-
cytes plus nonparenchymal cells (MxDJNK mice) does
reduce DEN-induced HCC (Fig. 3), provides important
insight into the mechanism of JNK-promoted HCC de-
velopment. These findings indicate that the protumori-
genic function of JNK may be localized to nonparenchy-
mal cells, rather than hepatocytes. Indeed, functions of
nonparenchymal cells are implicated in HCC develop-
ment (Maeda et al. 2005; Grivennikov et al. 2010).
Specifically, the release of IL1a by necrotic cells (Chen
et al. 2007; Sakurai et al. 2008), and the subsequent
expression of the protumorigenic cytokine IL6 (and also
TNFa in obese mice) by hepatic innate immune cells,
including Kupffer cells (Naugler et al. 2007; Park et al.
2010), may drive compensatory hepatocyte proliferation
and, subsequently, HCC (Fig. 7). It is therefore significant
that compound JNK deficiency in MxDJNK mice, but not
HDJNK mice, causes markedly decreased expression of IL6
and TNFa (Fig. 6). These data are consistent with the
conclusion that JNK is required for the expression of the
protumorigenic cytokines IL6 and TNFa by hepatic in-
nate immune cells during the development of HCC (Fig.
6B). Thus, the protumorigenic activity of JNK may be
mediated by a role for JNK in nonparenchymal cells (Fig.
3) in the creation of an inflammatory environment that
supports HCC development (Grivennikov et al. 2010).
The previously described genetic interactions between
Jnk1 and p21CIP1 (Hui et al. 2008) may therefore reflect an
inhibitory action of p21CIP1 on hepatic innate immune
cells, rather than hepatocytes. Studies using mice with
tissue-specific p21CIP1 deficiency will be required to
resolve this question.
The role of JNK in hepatocytes during
HCC development
Studies of mice with compound deficiency of JNK1 plus
JNK2 demonstrate that cell death and compensatory
JNK and hepatocellular carcinoma
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proliferation are key targets of JNK function in HCC (Fig.
5). Specifically, we find that compound JNK deficiency
in hepatocytes causes increased hepatocyte death and,
consequently, increased compensatory proliferation and
HCC development (Figs. 2, 5). The increased death caused
by compound JNK deficiency is consistent with previous
studies that demonstrate a role for JNK in cell survival
(Kuan et al. 1999; Lamb et al. 2003) and the presence of
JNK-independent pathways that can mediate hepatocyte
death (Das et al. 2009). Although the cell type of HCC
origin is unclear (Mishra et al. 2009), tumors detected
using Albumin-Cre transgenic mouse models of DEN-
induced HCC demonstrate efficient ablation of floxed
genes in tumor cells (Fig. 2E; Maeda et al. 2005). These
data suggest that JNK in hepatic parenchymal cells func-
tions to reduce tumor development in the DEN model of
HCC. This effect of JNK to influence hepatocyte death,
compensatory proliferation, and HCC development (Figs.
2, 5) is similar to the reported effects of hepatocyte-
specific deficiency of the NF-kB activator IKKb (Maeda
et al. 2005). Together, these data are consistent with the
proposed role of compensatory proliferation in hepatic
tumor development (Fausto 1999).
Conclusions
The results of this study demonstrate that JNK plays
a complex role in the development of HCC. JNK is
required for HCC development because it functions in
nonparenchymal cells to cause expression of protumori-
genic cytokines, including IL6 and TNFa. In contrast,
JNK in hepatocytes reduces tumor development by de-
creasing hepatocyte death and compensatory prolifera-
tion. It is likely that previous studies using mice with
whole-body knockout of Jnk1 or Jnk2 reflect a composite
phenotype derived from the cell type-specific functions of
JNK in hepatocytes and nonparenchymal cells.
We conclude that JNK both promotes and inhibits
tumor development in the DEN model of HCC. This
conclusion has implications for the more general role of
JNK in cancer. Both tumor promotion and inhibition by
JNK may contribute to cancer development (Davis 2000;
Whitmarsh and Davis 2007). This complicates the anal-
ysis of JNK pathway mutations that have been identified
in human cancer (Greenman et al. 2007; Kan et al. 2010).
Moreover, this dual role of JNK should be considered in
the context of the potential use of JNK as a therapeutic




We previously described Jnk1LoxP/LoxP mice (Das et al. 2009) and
Jnk2/mice (Yang et al. 1998). B6.Cg-Tg(Alb-cre)21Mgn/J mice
(Postic et al. 1999), B6.Cg-Tg(Mx1-cre)1Cgn/J mice (Kuhn et al.
1995), and C57BL/6J mice were obtained from The Jackson
Laboratories (stock numbers 003574, 003556, and 000664, re-
spectively). The mutant mice were maintained on a C57BL/6J
strain background (backcrossed 10 generations), andwere housed
in a facility accredited by the American Association for Labora-
tory Animal Care (AALAC). Deletion of floxed alleles in Mx1-
Cre mice was performed by treatment of 4-wk-old mice with 20
mg/g polyinosinic-polycytidylic acid (polyIC) (Mikkola et al.
2003) followed by recovery (4 wk). Control mice were similarly
injected with polyIC. PHx was performed on 10-wk-old mice
using methods described previously (Greene and Puder 2003).
The animal studies were approved by the Institutional Animal
Care and Use Committee (IACUC) of the University of Massa-
chusetts Medical School.
Genotype analysis
Genotype analysis was performed by PCR using genomic DNA
as the template. The Jnk1+ (540 base pairs [bp]) and Jnk1LoxP (330
bp) alleles were identified using the amplimers 59-AGGATTT
ATGCCCTCTGCTTGTC-39 and 59-GAACCACTGTTCCAAT
TTCCATCC-39. The Jnk1LoxP (1100 bp) and Jnk1D (400 bp) alleles
were identified using the amplimers 59-CCTCAGGAAGAAA
GGGCTTATTTC-39 and 59-GAACCACTGTTCCAATTTCCAT
CC-39. The Jnk2+ (400 bp) and Jnk2 (270 bp) alleles were
identified using the amplimers 59- GGAGCCCGATAGTATCGA
GTTACC-39, 59-GTTAGACAATCCCAGAGGTTGTGTG-39, and
59-CCAGCTCATTCCTCCACTCATG-39. Cre alleles (450 bp)
were detected using the amplimers 59-TTACTGACCGTACAC
CAAATTTGCCTGC-39 and 59- CCTGGCAGCGATCGCTATT
TTCCATGAGTG-39.
HCC assays
Carcinogen-induced HCC was studied using procedures de-
scribed previously (Sakurai et al. 2008). Two-week-old male mice
were treated by intraperitoneal (i.p.) injection with a single dose
(25 mg/kg) of DEN (Sigma, N0258) diluted in glyceryl triocta-
noate (Sigma, T9126). Control mice were injected with sol-
vent alone. The mice were euthanized at 38 wk of age to ex-
amine tumor development. Surface tumor size and number
were measured using stereomicroscopy (Maeda et al. 2005).
The Cre+/ genetic background altered the tumor burden in
the DEN-induced HCC studies; more tumors were found in
the Mx1-Cre+/ genetic background than in the Alb-Cre+/
genetic background (Figs. 2, 3). We therefore compared control
Figure 7. JNK functions in hepatocytes to reduce HCC de-
velopment and in nonparenchymal cells to promote HCC
development. JNK in nonparenchymal cells functions to pro-
mote HCC development by providing an inflammatory envi-
ronment that supports HCC, including the expression of the
protumorigenic cytokines IL6 and TNFa that contribute to
compensatory hepatocyte proliferation. However, JNK in hepa-
tocytes functions to reduce HCC development by promoting
hepatocyte survival, therefore decreasing IL1a release by ne-
crotic hepatocytes and the activation of hepatic innate immune
cells, including Kupffer cells, that express the protumorgenic
cytokine IL6.
Das et al.
642 GENES & DEVELOPMENT
 Cold Spring Harbor Laboratory Press on March 1, 2016 - Published by genesdev.cshlp.orgDownloaded from 
Mx1-Cre+/ mice with JNK-deficient Mx1-Cre+/ mice or con-
trol Alb-Cre+/ mice with JNK-deficient Alb-Cre+/ mice.
Serum analysis
Alanine transaminase (ALT) and aspartate aminotrasferase (AST)
activity in serum was measured using the ALTand AST Reagent
kit (Pointe Scientific) with a Tecan Sapphire microplate reader
(Tecan Trading AG). The serum concentration of cytokines was
measured by multiplexed ELISA using a Luminex 200 instru-
ment (Millipore).
Biochemical analysis
Immunoblot analysis was performed by probing with antibodies
to activated Caspase 3 (Cell Signaling, #9661) Sprouty2 (Abcam,
#ab50317), PTEN (Cell Signaling, #9198), p21 (Santa Cruz Bio-
technology, #SC 6246), and a-Tubulin (Sigma, #T5168). Immu-
noblots were quantitated using a LiCOR Odyssey imager. The
amount of total and phospho-JNK, ERK, p38 MAPK, and AKT in
tissue extracts was measured using a multiplexed ELISA kit (Bio-
Rad) and a Luminex 200 instrument (Millipore).
Quantitative RT–PCR assays (TaqMan) of mRNA expression
were performed using a 7500 Fast Real-Time PCRmachine (Applied
Biosystems) with total RNA prepared from tissues with an RNeasy
minikit (Qiagen). The probes were cFos (Mm00487425_m1),
cJun (Mm 00495062_s1), cMyc (Mm00487804_m1), Cyclin D1
(Mm00432359_m1), Il1a (00439621_m1), Il1b (Mm00434228_m1),
Il6 (Mm00446190_m1), JunB (Mm00492781_s1), JunD (Mm
00495088_s1), p15 (Mm00483241_m1), p21 (Mm 00432448_
m1), Pten (Mm01212532_m1), Socs3 (Mm00545913_s1), Spr2
(Mm00442344_m1), Tgfb1 (Mm03024053_m1), and Tnf
(Mm00443258_m1) (Applied Biosystems). The relative mRNA
expression was normalized by measuring the amount of Gapdh
RNA in each sample using TaqMan assays (Applied Biosystems,
4352339E-0904021).
We prepared RNA from tissue samples using the mirVana
microRNA isolation kit (Ambion) for the analysis of miR-21
expression using TaqMan assays (Applied Biosystems, miR-21
RT 2493). The relative miR-21 expression was normalized by
measuring the amount ofU6RNA in each sample using TaqMan
assays (Applied Biosystems,U6 RT1973).
Analysis of liver sections
Histology was performed using tissue fixed in 10% formalin for
24 h, dehydrated, and embedded in paraffin. Sections (7 mm) were
cut and stained using hematoxylin and eosin (American Master
Tech Scientific). Terminal deoxynucleotidyltransferase-medi-
ated nick end labeling (TUNEL) staining of deparafinized liver
sections was performed using the In Situ Cell Death Detection
kit Flourescein (Roche) following antigen retrieval (Antigen
Unmasking Solution, Vector Laboratories). Immunofluorescence
analysis of deparafinized liver sections was performed using
antigen retrieval (Vector Laboratories); incubation (1 h) with
3% bovine serum albumin (BSA), 1% normal goat serum, and
0.4% Triton X-100 in phosphate-buffered saline (PBS); incuba-
tion (12 h) at 4°C with a biotin-linked antibody to PCNA
(Zymed Laboratories, 13-3940) in PBS with 3% BSA; and
detection of immune complexes with Streptavidin-conjugated
Alexa fluor 633 (Invitrogen, S 21375) in PBS with 3% BSA. The
liver sections were mounted on glass slides. Nuclei were
stained with DAPI using Vectashield (Vector Laboratories).
Fluorescence microscopy was performed using a Leica SP2
confocal microscope.
The incorporation of BrdU was examined using liver sections
prepared from mice injected (i.p.) with 100 mg/g BrdU (dissolved
in saline) at 2 h prior to euthanasia. Livers were fixed in formalin,
dehydrated, and embedded in paraffin, and 4-mm sections were
prepared. Deparafinized liver sections were processed for antigen
retrieval and incubated with an antibody to BrdU (Biogenex,
#MU247-UC). Immune complexes were detected with a Strepta-
vidin/Biotin-based Link-Label Detection kit (Biogenex, Super-
sensitive Link label immunohistochemistry detection system)
and DAB substrate (Vector Laboratories, #SK4100).
Statistical analysis
Differences between groups were examined for statistical signif-
icance using the Student’s test or analysis of variance (ANOVA)
with the Fisher’s test. Kaplan-Meier analysis was performed
using the log-rank test.
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